UAS Labs Acquires Micropharma, Cardioviva Probiotics

<p>UAS Laboratories LLC acquired intellectual property assets of Micropharma Limited, developer of the probiotic strain Lactobacillus reuteri NCIMB 30242 (LRC&#8482;), and also took ownership of the pioneering Cardioviva&#8482; brand of probiotics.</p>

WAUSAU, Wis.—UAS Laboratories LLC acquired intellectual property assets of Micropharma Limited, developer of the probiotic strain Lactobacillus reuteri NCIMB 30242 (LRC™), and also took ownership of the pioneering Cardioviva™ brand of probiotics.

The companies have enjoyed a close relationship as partners and industry leaders in the probiotic space and were both winners of the 2014 NEXT Innovation Summit’s NutraAward presented at Natural Products Expo West. Micropharma accepted the best new ingredient award for the L. reuteri strain NCIMB 30242, which is backed by multiple gold standard human clinical trials. UAS Labs is proud to add this well-researched strain to its portfolio, which boasts the famous strain Lactobacillus acidophilus DDS®-1.

“The founders and employees at Micropharma have set the industry standard for taking a probiotic strain through the discovery and commercialization process," said Gregory Leyer, chief scientific officer for UAS Labs. “We are honored to have the opportunity to write the next successful chapter for this strain, brand and ultimately the emerging heart health category for probiotics."

Lakeview Equity Partners LLC, the majority owner of UAS Labs, provided funding to complete this acquisition and the recently completed $4 million state-of-the-art upgrade to its probiotic-focused manufacturing facility in central Wisconsin. This upgrade positions UAS Labs to continue to grow as an industry leader in probiotics.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish